Josh Cocklin

Director

Josh Cocklin is responsible for managing due diligence investigations for the firms clients in providing regulatory, compliance and legal advice and representation, particularly in relation to the healthcare and pharmaceutical sector. Josh has advised on a large number number of regulatory issues – including those involving the MHRA (including IAG), ICO and HMRC. He also has acted for and advised in relation to disputes with the NHS, GPhC and other healthcare regulators.

Josh has over 11 years’ regulatory, compliance and investigation experience – several years of which was spent heading up the investigations/litigation support team for a global investigation/intelligence firm. Josh is a Certified Fraud Examiner and a Member of the Association of Certified Fraud Examiners. Josh is also a Member of the Institute of Business Ethics, the Fraud Advisory Panel and the Chartered Institute of Legal Executives. He is retained as a board adviser to various organisations. Josh is a Magistrate assigned to the London bench and he is authorised to sit in the Crown Court to hear appeals from the Magistrates Court.

At present, Josh is assisting various businesses across Europe conduct due diligence investigations into their business partners, suppliers and customers. In addition to managing due diligence investigations, Josh is heavily involved in providing advice in relation to regulatory and compliance matters, particularly to healthcare and pharmaceutical clients.

Josh has recent and current experience as follows:

  • Advising and representing various holders of an MHRA WDA(H) with referrals to the Inspection Action Group IAG for compliance deficiencies arising out of the Human Medicines Regulations 2012 and the principles of Good Distribution Practice (GDP) including those licence holders facing proposed (and immediate) suspension and removal of the Responsible Person and other variations by the MHRA (via IAG).
  • Providing advice to pharmaceutical wholesalers on the development of quality management systems in compliance with the GDP guidelines and Human Medicines Regulations 2012.
  • Assisting a pharmacist the subject of an investigation by the relevant healthcare regulator – the General Pharmaceutical Council (GPHC), leading to the case being closed by the GPhC with no further action being taken at the pharmacist.
  • Advising a pharmacist in connection with an enquiry by NHS England.
  • Assisting pharmaceutical wholesalers in connection with regulatory enquiries, leading to no further action being taken both in respect of the regulatory matter (arising out of GDP and the Human Medicine Regulations) and the criminal enquiry (arising out of the Misuse of Drugs Act and Misuse of Drugs Regulations).
  • Provided representation to a wholesaler in connection with an enquiry by the MHRA relating to the dealing in high-value medicines, following a referral to the Inspection Action Group (IAG) as a result of serious deficiencies in respect of the Human Medicines Regulations 2012 and Good Distribution Practice.
  • Advising a director in respect of enquiries by the NHS Counter Fraud Authority.
  • Advising a WDA(H) holder (wholesaler of pharmaceutical products and medicines) in respect of exposure under the Misuse of Drugs Act, Misuse of Drugs Regulations, Human Medicines Regulations and GDP in respect of deficiencies identified by MHRA subsequently referred to IAG for consideration of suspension.
  • Advising in relation to a claim against the NHS in relation to its decision to refuse to pay a pharmacy for its claims.
  • Assisting a pharmaceutical wholesaler in connection with regulatory compliance enquiries, leading to no further action being taken both in respect of the regulatory matter and the fitness to practice enquiry.
  • Advising a regulated healthcare professional with simultaneous regulatory and fitness to practice proceedings arising out of the wholesaling of medicines, leading to no further action being taken following detailed representations.
  • Advising a pharmaceutical wholesaler in connection with  legal and compliance obligations under the Human Medicines Regulations 2012 and providing advice on inter alia how to comply with requests by a regulatory agencies (including the Medicines and Healthcare products Regulatory Agency – MHRA), leading to no further action being taken.
  • Investigated complex pan-European missing trader and VAT fraud to identify Defendants who would be subject to civil proceedings to recover funds that have been dishonestly obtained for the benefit of the client firm.Advising a regulated healthcare professional in connection with regulatory and professional enquiries relating to its dealings in high-value products across Europe, leading to a discontinued investigation after representations.
  • Providing advice to pharmacists, doctors and other healthcare professionals in respect of ongoing investigations and proceedings.
  • Advising a wholesaler in relation to its obligations in respect of money laundering and counter terrorist financing, leading to a successful inspection by the supervisory authority.
  • Providing advice and assistance to those seeking to apply for a WDA(H) from the Medicines and Healthcare Products Regulatory Agency – MHRA and preparing for inspections.
  • Advised businesses on risk-based due diligence investigations for large FMCG and retailer firms across Europe on their business partners, to assist client firms in managing their risk exposure across their businesses.

Josh published a fact-sheet for the Fraud Advisory Panel titled Due diligence on UK-based third parties (December 2015). He also wrote an article for Ethical Boardroom titled Transparency in supply chains (January 2016). He is currently contributing to other due diligence, risk/governance, and ethics articles shortly due for publication.

Contact Josh Cocklin for regulatory, compliance and legal assistance today.

Telephone: 0203 397 8958
E-mail: jc@truediligence.uk

Contact Us

Please leave us a message and we'll get back to you shortly.